The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.

Search Terms:

Investigator: Andrei Vlassenko
Project Title: Aerobic Glycolysis in the Development of Alzheimer�s Disease
Date: September 8, 2017
Request ID: S1706
Aim 1: Evaluate the role of AG as a function of preclinical and symptomatic stages of AD, and determine whether baseline AG predicts the rate of change in other biomarkers and cognitive measures, and if low baseline AG will be associated with the subsequent development of AD pathology and cognitive decline
Aim 2: Determine rate of change in AG in relation to rate of change in clinical assessments and biomarkers of AD; evaluate changes in AG and other PET measures of metabolism and circulation during the transition from no AD pathology to preclinical AD, and through the preclinical stages to symptomatic AD.
Aim 3:
Aim 4:

Investigator: Dmitriy Yablonskiy
Project Title: In vivo MRI Biomarkers of Microstructural Correlates of Brain Pathology in Preclinical and Early Alzheimer Disease
Date: July 21, 2017
Request ID: S1705
Aim 1: To develop a readily available, non-invasive quantitative in vivo MRI-based biomarker that can serve as a surrogate for Aβ accumulation in the brain
Aim 2: To establish specific quantitative and spatial patterns of GEPCI metrics abnormalities that would distinguish between normal brain, preclinical AD, and very mild AD
Aim 3: To test the hypothesis that the GEPCI metrics and/or changes in GEPCI metrics can be predictors of the disease progression
Aim 4: To validate GEPCI measurements against direct neuropathology

Investigator: Yi Su
Project Title: Absolute Quantification of Amyloid PET
Date: April 20, 2017
Request ID: S1704
Aim 1: Validating a reference region free method for amyloid PET quantification
Aim 2:
Aim 3:
Aim 4:

Investigator: Todd Braver
Project Title: Interaction of Motivation and Cognitive Control in Older Adult Decision Making
Date: April 14, 2017
Request ID: S1703
Aim 1: Examine age differences in cognitive control mechanisms that enable motivational integration
Aim 2:
Aim 3:
Aim 4:

Investigator: Jeffrey M. Zacks
Project Title: Everyday Memory in Aging and Alzheimer’s Disease
Date: March 27, 2017
Request ID: S1702
Aim 1: Test the hypothesis that age and biomarkers for AD neuropathology are associated with impairments in the ability to notice and remember changes.
Aim 2: Use an experimental approach to test one potential mechanism: reduced fidelity of medial temporal activity patterns leading to impaired detection of discrepancy.
Aim 3: Attempt to remediate age- and AD-related memory deficits by enhancing elders� encoding of new events in relation to related previous events with a cuing procedure.
Aim 4:

Investigator: John C. Morris
Project Title: Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer�s Disease
Date: March 14, 2017
Request ID: S1701
Aim 1: To show that loss of blood-brain barrier (BBB) integrity links vascular injury to neuronal injury in AD
Aim 2: Examine temporal relationship between BBB permeability, cerebral blood flow (CBF) and white matter lesions
Aim 3:
Aim 4:

Investigator: Jason Hassenstab
Project Title: Pilot Study: Ambulatory Cognitive Assessments
Date: October 26, 2016
Request ID: S1610
Aim 1: Determine the feasibility and utility of ambulatory cognitive assessments using measurment burst design.
Aim 2:
Aim 3:
Aim 4:

Investigator: Ganesh Babulal
Project Title: Racial differences in Alzheimer�s disease biomarkers and driving behavior
Date: October 18, 2016
Request ID: S1609
Aim 1: We will determine, in a sample of 60 older adults, aged 65 years and older, with normal baseline cognition (Clinical Dementia Rating of 0), whether there are differences in values of cerebrospinal fluid (CSF) biomarkers and imaging amyloid uptake between African Americans and Caucasians
Aim 2: In the same sample, we will examine whether there are differences in African Americans and Caucasians cross-sectionally and longitudinally in daily driving behavior using an in-vehicle recording device and on a road test
Aim 3:
Aim 4:

Investigator: Eric McDade
Project Title: Cerebrovascular Reactivity in the Presence of Cerebral Amyloid and Cerebrovascular Disease:
Date: August 21, 2016
Request ID: S1608
Aim 1: To explore the impact of cerebral amyloid on cerebrovascular reactivity
Aim 2: To explore the impact of age and vascular related comorbidities in the relationship of cerebrovascular reactivity and cerebral amyloid
Aim 3: To explore the the impact of cerebrovascular reactivity as a moderator of amyloid related cognitive impairment
Aim 4:

Investigator: B, Joy Snider (WU site)
Project Title: Protocol 221AD301 A phase 3 Multicenter, RCT to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer�s Disease (ENGAGE Study)
Date: August 17, 2016
Request ID: S1607
Aim 1: Evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the CDR-SB score as compared with placebo in subjects with early AD.
Aim 2: Evaluate the efficacy of aducanumab on MMSE, ADAS-Cog13, ADCS-ADL
Aim 3:
Aim 4: